Combined CDC COVID-19/Influenza Test Amended to Include Promega Maxwell® RSC 48 and CSC 48 Instruments, Maxwell® RSC Viral Total Nucleic Acid Purification Kit

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005075/en/

The Promega Maxwell® CSC 48 (pictured), Maxwell® RSC 48 and Maxwell® RSC Viral Total Nucleic Acid Purification Kit are now authorized options for labs running the US Centers for Disease Control’s (CDC) Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. (Photo: Business Wire)

The Promega Maxwell® RSC 48 benchtop instrument is an automated nucleic acid purification platform that processes up to 48 samples simultaneously. The Maxwell® CSC 48 nucleic acid extraction system is an in vitro diagnostic medical device specifically designed for clinical laboratories. The Maxwell® RSC Viral Total Nucleic Acid Purification Kit can be used with either instrument to purify viral RNA from SARS-CoV-2 test samples.

Multiplex Tests for SARS-CoV-2, Influenza

Multiplex tests, such as the Flu SC2 Multiplex Assay, can detect and differentiate RNA from SARS-CoV-2, influenza A virus, and influenza B virus from a single patient sample. This enables:

• labs to conserve materials while also processing more tests
• clinicians to differentiate between COVID-19 and flu, since symptoms can be similar
• health officials to conduct ongoing flu surveillance while also testing for SARS-CoV-2

“Multiplex molecular tests are crucial as the flu season overlaps with the COVID-19 pandemic, and we’re glad that Promega is able to continue to support laboratories by providing them more options as testing evolves and advances,” says Heather Tomlinson, Director of Clinical Diagnostics at Promega.

Promega SARS-CoV-2 Support

Maxwell® RSC 48, Maxwell® CSC 48, Maxwell® RSC Viral Total Nucleic Acid Purification Kit and GoTaq® Probe 1-Step RT-qPCR System are already included, for emergency use, in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT–PCR Diagnostic Panel, which tests for COVID-19 only.

Promega reagents, assays and benchtop instruments are being used around the world for SARS-CoV-2 testing, research, and vaccine development.

• Bioluminescent immunoassay to detect SARS-CoV-2 antibodies: The Lumit™ Dx SARS-CoV-2 Immunoassay is a qualitative IVD test intended to detect antibodies to SARS-CoV-2 in serum or plasma.
• Technology to accelerate COVID-19 testing: XpressAmp™ Direct Amplification Reagents allow labs to skip the RNA extraction step of the workflow.
• Reagents to enable testing an estimated 550 million samples: Since January 2020, Promega has rapidly increased production to support labs testing for SARS-CoV-2 worldwide.

Tools used for COVID-19 applications are a small subset of the 4,000 products Promega manufactures and distributes globally, serving research, pharma, clinical, forensic and applied markets. These products are used for a myriad of applications in human health, disease, genetic identity, drug development, clinical diagnostics and more.

To learn more about Promega SARS-CoV-2 products and Promega technical support visit: www.promega.com/covid19

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit www.promega.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005075/en/